P-Glycoprotein Function at the Blood–Brain Barrier in Humans Can Be Quantified with the Substrate Radiotracer 11C-N-Desmethyl-Loperamide
Open Access
- 17 March 2010
- journal article
- clinical trial
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 51 (4), 559-566
- https://doi.org/10.2967/jnumed.109.070151
Abstract
Permeability-glycoprotein (P-gp), an efflux transporter in several organs, acts at the blood–brain barrier to protect the brain from exogenous toxins. P-gp almost completely blocks brain entry of the PET radiotracer 11C-N-desmethyl-loperamide (11C-dLop). We examined the ability of 11C-dLop to quantify P-gp function in humans after increasing doses of tariquidar, an inhibitor of P-gp. Methods: Seventeen healthy volunteers had a total of 23 PET scans with 11C-dLop at baseline and after increasing doses of tariquidar (2, 4, and 6 mg/kg intravenously). A subset of subjects received PET with 15O-H2O to measure cerebral blood flow. Brain uptake of 11C-dLop was quantified in 2 ways. Without blood data, uptake was measured as area under the time–activity curve in the brain from 10 to 30 min (AUC10–30). With arterial blood data, brain uptake was quantified with compartmental modeling to estimate the rates of entry into (K1) and efflux from (k2) the brain. Results: Brain uptake of radioactivity was negligible at baseline and increased only slightly (∼30%) after 2 mg of tariquidar per kilogram. In contrast, 4 and 6 mg of tariquidar per kilogram increased brain uptake 2- and 4-fold, respectively. Greater brain uptake reflected greater brain entry (K1), because efflux (k2) and cerebral blood flow did not differ between tariquidar-treated and untreated subjects. In the subjects who received the highest dose of tariquidar (and had the highest brain uptake), regional values of K1 correlated linearly with absolute cerebral blood flow, consistent with high single-pass extraction of 11C-dLop. AUC10–30 correlated linearly with K1. Conclusion: P-gp function at the blood–brain barrier in humans can be quantified using PET and 11C-dLop. A simple measure of brain uptake (AUC10–30) may be used as a surrogate of the fully quantified rate constant for brain entry (K1) and thereby avoid arterial sampling. However, to dissect the function of P-gp itself, both brain uptake and the influx rate constant must be corrected for radiotracer delivery (blood flow).This publication has 25 references indexed in Scilit:
- Imaging the Function of P-Glycoprotein With Radiotracers: Pharmacokinetics and In Vivo ApplicationsClinical Pharmacology & Therapeutics, 2009
- A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with VinorelbineClinical Cancer Research, 2009
- Human Brain Imaging and Radiation Dosimetry of 11C-N-Desmethyl-Loperamide, a PET Radiotracer to Measure the Function of P-GlycoproteinJournal of Nuclear Medicine, 2009
- P-Glycoprotein Function at the Blood–Brain Barrier Imaged Using 11C-N-Desmethyl-Loperamide in MonkeysJournal of Nuclear Medicine, 2008
- Several major antiepileptic drugs are substrates for human P-glycoproteinNeuropharmacology, 2008
- Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates.2003
- Modulation of P-glycoprotein Transport Activity in the Mouse Blood-Brain Barrier by RifampinJournal of Pharmacology and Experimental Therapeutics, 2003
- Mechanisms of Cancer Drug ResistanceAnnual Review of Medicine, 2002
- Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration.2000
- Increased drug delivery to the brain by P-glycoprotein inhibitionClinical Pharmacology & Therapeutics, 2000